Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2011

Open Access 01-12-2011 | Review

A short account of metastatic bone disease

Authors: Liviu Feller, Beverley Kramer, Johan Lemmer

Published in: Cancer Cell International | Issue 1/2011

Login to get access

Abstract

In adults, bone is the preferential target site for metastases from primary cancers of prostate, breast, lungs and thyroid. The tendency of these cancers to metastasize to bone is determined by the anatomical distribution of the blood vessels, by the genetic profile of the cancer cells and by the biological characteristics of the bone microenvironment that favour the growth of metastatic cells of certain cancers.
Metastases to bone may have either an osteolytic or an ostoblastic phenotype. The interaction in the bone microenvironment between biological factors secreted by metastatic cells, and by osteoblasts and osteoclasts, and the osteolytic and osteoblastic factors released from the organic matrix mediate a vicious cycle characterized by metastatic growth and by ongoing progressive bone destruction. This interaction determines the phenotype of the metastatic bone disease.
Literature
1.
Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003, 3: 537-549. 10.1016/S1535-6108(03)00132-6.CrossRefPubMed
2.
3.
Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, Ponomarev V, Gerald WL, Blasberg R, Massague J: Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest. 2005, 115: 44-55.PubMedCentralCrossRefPubMed
4.
Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, Kaufmann M, Diebold J, Arnholdt H, Muller P, Bischoff J, Harich D, Schlimok G, Riethmuller G, Eils R, Klein CA: From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA. 2003, 100: 7737-7742. 10.1073/pnas.1331931100.PubMedCentralCrossRefPubMed
5.
Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmüller G, Klein CA: Systemic spread is an early step in breast cancer. Cancer Cell. 2008, 13: 58-68. 10.1016/j.ccr.2007.12.003.CrossRefPubMed
6.
Nguyen DX, Bos PD, Massague J: Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009, 9: 274-284. 10.1038/nrc2622.CrossRefPubMed
7.
Feller L, Bouckaert M, Chikte UM, Wood NH, Khammissa RA, Meyerov R, Lemmer J: A short account of cancer--specifically in relation to squamous cell carcinoma. SADJ. 2010, 65: 322-324.PubMed
8.
Logothetis CJ, Lin SH: Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer. 2005, 5: 21-28. 10.1038/nrc1528.CrossRefPubMed
9.
10.
Roato I, Grano M, Brunetti G, Colucci S, Mussa A, Bertetto O, Ferracini R: Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. FASEB J. 2005, 19: 228-230.PubMed
11.
Major PP, Cook RJ, Lipton A, Smith MR, Terpos E, Coleman RE: Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer. 2009, 9: 272-10.1186/1471-2407-9-272.PubMedCentralCrossRefPubMed
12.
Sun YX, Fang M, Wang J, Cooper CR, Pienta KJ, Taichman RS: Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate. 2007, 67: 61-73. 10.1002/pros.20500.CrossRefPubMed
13.
Wels J, Kaplan RN, Rafii S, Lyden D: Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev. 2008, 22: 559-574. 10.1101/gad.1636908.PubMedCentralCrossRefPubMed
14.
Wang J, Loberg R, Taichman RS: The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev. 2006, 25: 573-587.CrossRefPubMed
15.
Taichman RS, Loberg RD, Mehra R, Pienta KJ: The evolving biology and treatment of prostate cancer. J Clin Invest. 2007, 117: 2351-2361. 10.1172/JCI31791.PubMedCentralCrossRefPubMed
16.
17.
Pienta KJ, Loberg R: The "emigration, migration, and immigration"of prostate cancer. Clin Prostate Cancer. 2005, 4: 24-30.CrossRefPubMed
18.
Sun YX, Schneider A, Jung Y, Wang J, Dai J, Cook K, Osman NI, Koh-Paige AJ, Shim H, Pienta KJ, Keller ET, McCauley LK, Taichman RS: Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res. 2005, 20: 318-329.CrossRefPubMed
19.
Guise TA, Kozlow WM, Heras-Herzig A, Padalecki SS, Yin JJ, Chirgwin JM: Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer. 2005, 5: S46-S53. 10.3816/CBC.2005.s.004.CrossRefPubMed
20.
Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002, 2: 584-593. 10.1038/nrc867.CrossRefPubMed
21.
Schwartz GG: Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases. Cancer Epidemiol Biomarkers Prev. 2008, 17: 478-483. 10.1158/1055-9965.EPI-07-2747.CrossRefPubMed
22.
Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD: The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003, 349: 2483-2494. 10.1056/NEJMoa030847.CrossRefPubMed
23.
Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET: Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res. 2005, 65: 8274-8285. 10.1158/0008-5472.CAN-05-1891.CrossRefPubMed
24.
Li ZG, Yang J, Vazquez ES, Rose D, Vakar-Lopez F, Mathew P, Lopez A, Logothetis CJ, Lin SH, Navone NM: Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene. 2008, 27: 596-603. 10.1038/sj.onc.1210694.CrossRefPubMed
25.
Keller ET, Zhang J, Cooper CR, Smith PC, McCauley LK, Pienta KJ, Taichman RS: Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev. 2001, 20: 333-349. 10.1023/A:1015599831232.CrossRefPubMed
26.
Brown JE, Coleman RE: The present and future role of bisphosphonates in the management of patients with breast cancer. Breast Cancer Res. 2002, 4: 24-29.PubMedCentralCrossRefPubMed
27.
Brown JE, Neville-Webbe H, Coleman RE: The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer. 2004, 11: 207-224. 10.1677/erc.0.0110207.CrossRefPubMed
28.
Bringhurst F, Demay M, Krane S, Kronenberg H: Bone and Mineral Metabolism in Health and Disease. Harrison's Principles of Internal Medicine. Edited by: Kasper D, Hauser S, Longo D, Jameson J, Loscaizo J. 2008, New York: McGraw-Hill, 2365-2376. 17
29.
Koeneman KS, Yeung F, Chung LW: Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate. 1999, 39: 246-261. 10.1002/(SICI)1097-0045(19990601)39:4<246::AID-PROS5>3.0.CO;2-U.CrossRefPubMed
30.
Bai YD, Yang FS, Xuan K, Bai YX, Wu BL: Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment. Med Hypotheses. 2008, 71: 256-258. 10.1016/j.mehy.2008.03.021.CrossRefPubMed
31.
Roodman GD: Mechanisms of bone metastasis. N Engl J Med. 2004, 350: 1655-1664. 10.1056/NEJMra030831.CrossRefPubMed
32.
Glass DA, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G: Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005, 8: 751-764. 10.1016/j.devcel.2005.02.017.CrossRefPubMed
33.
Romas E: Clinical applications of RANK-ligand inhibition. Intern Med J. 2009, 39: 110-116. 10.1111/j.1445-5994.2008.01732.x.CrossRefPubMed
34.
Fenton R, Longo D: Cancer Cell Biology and Angiogenesis. Harrison's Principles of Internal Medicine. Edited by: Kasper D, Hauser S, Longo D, Jameson J, Loscaizo J. 2008, New York: McGraw-Hill, 498-513. 17
35.
Biskobing DM, Fan X, Rubin J: Characterization of MCSF-induced proliferation and subsequent osteoclast formation in murine marrow culture. J Bone Miner Res. 1995, 10: 1025-1032.CrossRefPubMed
36.
Yagiz K, Rittling SR: Both cell-surface and secreted CSF-1 expressed by tumor cells metastatic to bone can contribute to osteoclast activation. Exp Cell Res. 2009, 315: 2442-2452. 10.1016/j.yexcr.2009.05.002.PubMedCentralCrossRefPubMed
37.
Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, Vessella R, Corey E, Padalecki S, Suva L, Chirgwin JM: Basic mechanisms responsible forb osteolytic and osteoblastic bone metastases. Clin Cancer Res. 2006, 12: 6213s-6216s. 10.1158/1078-0432.CCR-06-1007.CrossRefPubMed
38.
Guise TA: Molecular mechanisms of osteolytic bone metastases. Cancer. 2000, 88: 2892-2898. 10.1002/1097-0142(20000615)88:12+<2892::AID-CNCR2>3.0.CO;2-Y.CrossRefPubMed
39.
Yoneda T: Cellular and molecular basis of preferential metastasis of breast cancer to bone. J Orthop Sci. 2000, 5: 75-81. 10.1007/s007760050012.CrossRefPubMed
40.
Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, Lowen D, Javni J, Miller FR, Slavin J, Anderson RL: A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis. 1999, 17: 163-170. 10.1023/A:1006689719505.CrossRefPubMed
41.
Jacob K, Webber M, Benayahu D, Kleinman HK: Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Res. 1999, 59: 4453-4457.PubMed
42.
Roato I, D'Amelio P, Gorassini E, Grimaldi A, Bonello L, Fiori C, Delsedime L, Tizzani A, De Libero A, Isaia G, Ferracini R: Osteoclasts are active in bone forming metastases of prostate cancer patients. PloS one. 2008, 3: e3627-10.1371/journal.pone.0003627.PubMedCentralCrossRefPubMed
43.
Darby S, Cross SS, Brown NJ, Hamdy FC, Robson CN: BMP-6 over-expression in prostate cancer is associated with increased Id-1 protein and a more invasive phenotype. J Pathol. 2008, 214: 394-404. 10.1002/path.2292.CrossRefPubMed
44.
Chung LW, Baseman A, Assikis V, Zhau HE: Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol. 2005, 173: 10-20. 10.1097/01.ju.0000141582.15218.10.CrossRefPubMed
45.
Loberg RD, Logothetis CJ, Keller ET, Pienta KJ: Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol. 2005, 23: 8232-8241. 10.1200/JCO.2005.03.0841.CrossRefPubMed
46.
Feller L, Wood NH, Khammissa RA, Chikte UM, Bouckaert M, Lemmer J: Bisphosphonate-related osteonecrosis of the jaw. SADJ. 2011, 66: 30-32.PubMed
47.
Barton MK: Denosumab an option for patients with bone metastasis from breast cancer. CA Cancer J Clin. 2011, 61: 135-136. 10.3322/caac.20116.CrossRefPubMed
48.
Coleman R, Brown J, Terpos E, Lipton A, Smith MR, Cook R, Major P: Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev. 2008, 34: 629-639. 10.1016/j.ctrv.2008.05.001.PubMedCentralCrossRefPubMed
49.
Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE: Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005, 97: 59-69. 10.1093/jnci/dji002.CrossRefPubMed
50.
Seibel MJ: Clinical use of markers of bone turnover in metastatic bone disease. Nat Clin Pract Oncol. 2005, 2: 504-517.CrossRefPubMed
51.
Seibel MJ: The use of molecular markers of bone turnover in the management of patients with metastatic bone disease. Clin Endocrinol. 2008, 68: 839-849. 10.1111/j.1365-2265.2007.03112.x.CrossRef
52.
Cremers S, Garnero P: Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls. Drugs. 2006, 66: 2031-2058. 10.2165/00003495-200666160-00001.CrossRefPubMed
53.
Huang Q, Ouyang X: Biochemical-markers for the diagnosis of bone metastasis: A review in clinical. Cancer Epidemiol. 2011
54.
Hirshberg A, Leibovich P, Buchner A: Metastatic tumors to the jawbones: analysis of 390 cases. J Oral Pathol Med. 1994, 23: 337-341. 10.1111/j.1600-0714.1994.tb00072.x.CrossRefPubMed
55.
D'Silva NJ, Summerlin DJ, Cordell KG, Abdelsayed RA, Tomich CE, Hanks CT, Fear D, Meyrowitz S: Metastatic tumors in the jaws: a retrospective study of 114 cases. J Am Dent Assoc. 2006, 137: 1667-1672.CrossRefPubMed
56.
Hirshberg A, Shnaiderman-Shapiro A, Kaplan I, Berger R: Metastatic tumours to the oral cavity - pathogenesis and analysis of 673 cases. Oral Oncol. 2008, 44: 743-752. 10.1016/j.oraloncology.2007.09.012.CrossRefPubMed
57.
Irani S: Metastasis to head and neck area: a 16-year retrospective study. Am J Otolaryngol. 2011, 32: 24-27. 10.1016/j.amjoto.2009.09.006.CrossRefPubMed
58.
van der Waal RI, Buter J, van der Waal I: Oral metastases: report of 24 cases. Br J Oral Maxillofac Surg. 2003, 41: 3-6. 10.1016/S0266-4356(02)00301-7.CrossRefPubMed
59.
Ertas U, Yalcin E, Erdogan F: Invasive ductal carcinoma with multiple metastases to facial and cranial bones: a case report. Eur J Dent. 2010, 4: 334-337.PubMedCentralPubMed
60.
Katsnelson A, Tartakovsky JV, Miloro M: Review of the literature for mandibular metastasis illustrated by a case of lung metastasis to the temporomandibular joint in an HIV-positive patient. J Oral Maxillofac Surg. 2010, 68: 1960-1964. 10.1016/j.joms.2009.07.075.CrossRefPubMed
Metadata
Title
A short account of metastatic bone disease
Authors
Liviu Feller
Beverley Kramer
Johan Lemmer
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2011
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-11-24

Other articles of this Issue 1/2011

Cancer Cell International 1/2011 Go to the issue

Primary research

Chalcone-imidazolone conjugates induce apoptosis through DNA damage pathway by affecting telomeres

Primary research

The role of Eag and HERG channels in cell proliferation and apoptotic cell death in SK-OV-3 ovarian cancer cell line

Primary research

SKY analysis revealed recurrent numerical and structural chromosome changes in BDII rat endometrial carcinomas

Primary research

Involvement of the epidermal growth factor receptor in the modulation of multidrug resistance in human hepatocellular carcinoma cells in vitro

Primary research

The chemopreventive effect of Ginkgo biloba and Silybum marianum extracts on hepatocarcinogenesis in rats

Review

IFN-γ, IL-17 and TGF-β involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits